In the shadow of President Trump's efforts to lower drug prices, the Medicare drug price negotiation process that began in ...

That question is at the heart of an unusual challenge that the pharma company Novo Nordisk is pursuing against ... have major ramifications for the Medicare drug price negotiation program, a ...

PITTSBURGH (CN) — Bashing a Biden-era law that gives Medicare the power to directly negotiate the price of certain high-cost prescription drugs, an attorney for the pharmaceutical giant Novo Nordisk ...

That question is at the heart of an unusual challenge that the pharma company Novo Nordisk is pursuing against ... have major ramifications for the Medicare drug price negotiation program, a ...

Novo Nordisk’s shock decision to oust its chief executive has resulted in the Ozempic maker once again becoming Europe’s ...

Novo Nordisk had a head start ... and some have refused to cover them. In most cases, Medicare will not pay for the drugs to treat obesity. The Trump administration recently rejected a Biden ...

However, a spokesperson for Novo Nordisk implied the Danish drugmaker plans to continue lobbying for expanded Medicare coverage of GLP-1s. Novo Nordisk is “committed to ensuring that people ...

We had not assumed this proposed rule would pass, and we continue to think Novo and Lilly will gain Medicare obesity drug coverage via overlapping indications with time, such as Zepbound’s ...

Novo Nordisk said on Thursday it plans to start late-stage trials of amycretin injection and oral drugs during the first ...

LONDON (Reuters) -Drugmaker Novo Nordisk is once again Europe's largest company by market capitalisation, rising above German ...

Novo Nordisk will pay U.S. biotech Deep Apple Therapeutics up to $812 million in a partnership deal aimed at developing drugs to treat cardiometabolic diseases, including obesity.